17 Apr 2024

CSL Seqirus: Project Banksia

article image

Start Date: 17 Apr 2024

Start Time: 10:00 am

End Time: 11:00 am

Location: Online Event

Join us for an insightful industry briefing on Project Banksia, hosted by CSL Seqirus and ICN Victoria. Gain valuable insights into the project scope, requirements, and opportunities.

Project Overview

CSL Seqirus, the world’s second largest influenza vaccine provider announced plans to construct a new world-class biotech manufacturing facility in Melbourne, Australia to supply influenza vaccines to Australia and the rest of the world, plus Australian antivenoms and Q-Fever vaccine. CSL Seqirus is a wholly owned subsidiary of CSL Limited, which will invest more than AUD$800 million in capital expenditure to construct the facility.

The building is expected to be operational by mid-2026.The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

This is a free event, please book here to receive the online briefing link and event updates.

You can find out more about Project Banksia and register your Expression of Interest on the ICN Gateway here

#InfluenzaVaccine #Vaccination #ICNVic #HelpLocalWin


ICN help desk

Phone 1300 961 139 (within Australia)
Phone +61 2 6285 2033 (outside Australia)
Email helpdesk@icncopy